Skip to content

Advancing Gene Therapy with Higher Confidence

Bringing human biology into early gene therapy development can be easily achieved
by using the iPSC-based Ncardia platform

Contact us

We help you select the most promising gene therapy candidate earlier with our dependable iPSC-platform

Despite the great potential of gene therapies, only a few drugs have received market approval from regulators. To effectively bring next-gen gene therapies from bench to bedside, there is a strong need for alternative testing platforms that recapitulate human pathophysiology and help making accurate predictions.

Human induced pluripotent stem cells (iPSC)-derived models are a promising alternative to support and supplement animal testing. They recapitulate disease hallmarks in vitro and can be integrated in discovery to facilitate the selection of the most promising candidates, saving resources and reducing the translational gap.

Benefits of Ncardia Solutions

High Reproducibility

Consistent results with our optimized assays

Predictive Responses

Testing on relevant
human biology

Quick Turnaround

A team focused on timely delivery of reliable data

Gaining Confidence in Essential Stages

What we can do for you

With the Ncardia platform, we facilitate your decision-making steps during gene therapy development by integrating human models and clinically relevant readouts. 

  • Test AAV selectivity and toxicity
  • Quantify transgene expression
  • Determine AAV transduction efficiency
  • Study AAV efficacy to rescue disease phenotypes

Whether you opt for our ready-to-use assays or require a custom solution, our expert team is ready to assist you. 

Ncardia gene therapy services

Your Trusted Partner to Maximize Long-term Success

Define your Needs

We work with you to understand your specifications and co-develop a plan

Plan the Process

We detail a project plan with clear timelines and milestones to match your needs

Execute and Report

Follow project progress with frequent and transparent communication

Plan for the Future

We analyze the data and discuss how to best support your next steps

 

Contact Us

If you're ready to explore how to accelerate the development of your gene therapy with our leading iPSC-based platform, we'd welcome the opportunity to introduce you to Ncardia.

Kim Riegman, PhD Senior Scientist
Kim 2